Rekombinanter PDCD1 (Pembrolizumab Biosimilar) Antikörper

Produktnummer ABIN7200668

Produktdetails anti-PDCD1 (Pembrolizumab Biosimilar) Antikörper

Target: PDCD1 (Pembrolizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PDCD1 (Pembrolizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Verwendungszweck: Pembrolizumab Biosimilar, Human PD-1 Monoclonal Antibody

Spezifität: The in vivo grade pembrolizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1 or PD1), antagonizing its interaction with its known ligands PD-L1 or PDL1, and PD-L2 or PDL2.

Produktmerkmale: Recombinant Humanized IgG4 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody pembrolizumab biosimilar was produced in the pembrolizumab biosimilar CHO stable cell line.

Isotyp: IgG4 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pembrolizumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu PDCD1 (Pembrolizumab Biosimilar)

Target: PDCD1 (Pembrolizumab Biosimilar)

Abstract: PDCD1 (Pembrolizumab Biosimilar) Produkte

Substanzklasse: Biosimilar

Hintergrund: What is Pembrolizumab biosimilar research grade? Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. Pembrolizumab Biosimilar uses the same protein sequences as the therapeutic antibody pembrolizumab.